Fundz
Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every contract, funding round, exec hire, and M&A move on Bio-Techne — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plansBook a 15-min walkthrough
▶
Watch the 2-minute tour · with sound

Bio-Techne Corporation and ALZpath, Inc Announce Strategic Partnership to Advance Neurodegenerative Disease Research

Nov 18, 2024•over 1 year ago

Contract Type

partnership

MinneapolisManufacturingBiotechnologyHealth CareScience And EngineeringBiotechnology Research

Description

Bio-Techne Corporation and ALZpath, Inc have announced a strategic partnership to accelerate breakthroughs in neurodegenerative disease research and treatment, particularly in Alzheimer's disease. The collaboration aims to leverage Bio-Techne's Ella™ fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay.

Company Information

Company

Bio-Techne

Location

Minneapolis, Minnesota, United States

About

Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. They design and manufacture products that enable researchers and healthcare professionals to improve patients' lives. Bio-Techne partners with Wilson Wolf to create tailored products for G-Rex® Bioreactors, focusing on high throughput closed-system manufacturing.

Predictive Intelligence
Strategic

ML-powered predictions for Bio-Techne's next move

Learn about Strategic plan

Related People

Suggested for you

Sign in to view contact details

Sign in to view contact details

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months